Tuberculosis (TB) along with acquired immune deficiency syndrome and malaria rank
among the top three fatal infectious diseases which pose threat to global public health …

Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

Background Linezolid was recently re‐classified as a Group A drug by the World Health
Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and …

Tuberculosis (TB) is a prominent infective disease and a major reason of mortality/morbidity
globally. Mycobacterium tuberculosis causes a long-lasting latent infection in a significant …

Background Drug-resistant pulmonary tuberculosis (DR-TB) is a significant public health
issue that considerably deters the ongoing TB control efforts in India. The purpose of this …

Emergence of extensively drug-resistant tuberculosis (XDR-TB) has significantly threatened
to jeopardize global efforts to control TB, especially in HIV endemic regions. XDR-TB is …

Control of Mycobacterium tuberculosis infection continues to be an issue, particularly in
countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The …

Objective Drug-resistant tuberculosis (DR-TB) is a major global public health threat. India, as
it shares a large fraction of the world's TB burden, is currently at a critical phase due to the …

Diagnostic development must occur in parallel with drug development to ensure the
longevity of new treatment compounds. Despite an increasing number of novel and …

Background Tuberculosis (TB) is still a global health problem mainly due to development of
resistance and co-infection with the Human immune Virus (HIV). Treatment of multi and …